Considering that little success has been achieved with inhibitors targeting PI3K/Akt for cancer therapy and TAM being evaluated in clinical trials for treatment of malignant gliomas, our findings suggest that secretory Par-4 can be induced by a combination treatment of TAM and Akt inhibitors to effectively kill cancer cells. The gene discussed is PAWR; the disease is cancer.